论文部分内容阅读
目的探讨更昔洛韦治疗儿童EB病毒感染的效果,寻找适合临床的最佳治疗方案。方法搜集EB病毒感染患儿共90例,随机分为两组,对照组采用一般对症治疗,酌情使用抗生素。而治疗组在上述常规治疗基础上,加用更昔洛韦抗EB病毒治疗,用量5 mg/kg,每12 h一次静脉点滴,静滴时间不少于1 h,疗程10~14 d。比较两组热程、咽峡及扁桃体恢复时间、淋巴结缩小时间、肝功能恢复时间、平均住院天数。并根据上述结果按有效、显效和无效进行比较。结果治疗组热程(7.64±2.34)d、淋巴结明显缩小所需时间(5.38±1.85)d、平均住院日(9.44±2.31)d,对照组热程(10.36±2.21)d、淋巴结明显缩小所需时间(8.95±2.14)d、平均住院日(12.07±2.36)d,治疗组各项指标均短于对照组(P<0.05);治疗后两组患儿肝脏、脾脏缩至正常及肝酶改善情况有统计学差异(P<0.05);治疗组显效率(60.00%)明显高于对照组(44.40%),两组比较,差异有统计学意义(P<0.05)。结论更昔洛韦治疗儿童EB病毒感染安全有效,是值得推广的治疗EB病毒感染的有效药物。
Objective To investigate the effect of ganciclovir in the treatment of children with Epstein-Barr virus (EBV) infection and to find the best treatment plan for clinical use. Methods A total of 90 children with Epstein-Barr virus (EBV) infection were collected and randomly divided into two groups. The control group received general symptomatic treatment and antibiotics were used as appropriate. The treatment group on the basis of the above conventional treatment, add ganciclovir anti-Epstein-Barr virus treatment, the amount of 5 mg / kg, once every 12 h intravenous drip, intravenous drip time of not less than 1 h, the course of 10 to 14 d. Comparison of the two groups of heat, angina and tonsil recovery time, lymph node reduction time, liver function recovery time, the average length of stay. And based on the above results by the effective, effective and ineffective to compare. Results The average duration of hospital stay was (9.44 ± 2.31) days in the treatment group (7.64 ± 2.34) days, the lymph node was significantly reduced (5.38 ± 1.85) days and the control group was (10.36 ± 2.21) days, the lymph node was significantly reduced (8.95 ± 2.14) d and average length of stay (12.07 ± 2.36) d, and the indexes in the treatment group were shorter than those in the control group (P <0.05). After treatment, the liver and spleen were reduced to normal and liver enzymes (P <0.05). The effective rate (60.00%) in the treatment group was significantly higher than that in the control group (44.40%). The difference between the two groups was statistically significant (P <0.05). Conclusion Ganciclovir is safe and effective in treating children with Epstein-Barr virus (EBV) infection and is worthy of promotion as an effective drug for the treatment of Epstein-Barr virus infection.